Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NITE
CUSIPN/A
Phone646-522-8445
Debt
Debt-to-Equity RatioN/A
Current Ratio12.69
Quick Ratio12.69
Price-To-Earnings
Trailing P/E Ratio-9.29
Forward P/E Ratio-7.80
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.48 per share
Price / Book3.38
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees23
Outstanding Shares28,100,000
Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions
What is Nightstar Therapeutics' stock symbol?
Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."
How were Nightstar Therapeutics' earnings last quarter?
Nightstar Therapeutics PLC (NASDAQ:NITE) released its earnings results on Wednesday, June, 6th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.12. View Nightstar Therapeutics' Earnings History.
When is Nightstar Therapeutics' next earnings date?
What price target have analysts set for NITE?
6 equities research analysts have issued 1 year price targets for Nightstar Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they expect Nightstar Therapeutics' stock price to reach $28.50 in the next twelve months. View Analyst Ratings for Nightstar Therapeutics.
What are Wall Street analysts saying about Nightstar Therapeutics stock?
Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
- 1. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (6/6/2018)
- 2. Mizuho analysts commented, "We’ve included links to the various abstracts below along with our thoughts on some of the abstracts ahead of the conference." (4/27/2018)
Who are some of Nightstar Therapeutics' key competitors?
Some companies that are related to Nightstar Therapeutics include Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), Acorda Therapeutics (ACOR), Audentes Therapeutics (BOLD), Cellectis (CLLS), Iovance Biotherapeutics (IOVA), Adaptimmune Therapeutics (ADAP), DBV Technologies (DBVT), BAVARIAN NORDIC/S (BVNRY), Solid Biosciences (SLDB), Coherus Biosciences (CHRS) and La Jolla Pharmaceutical (LJPC).
Who are Nightstar Therapeutics' key executives?
Nightstar Therapeutics' management team includes the folowing people:
- Mr. David Fellows, CEO & Director (Age 61)
- Mr. Senthil Sundaram, CFO & Principal Accounting Officer (Age 40)
- Dr. Gregory Robinson Ph.D., Chief Scientific Officer (Age 59)
- Mr. Aniz Girach, Chief Medical Officer
- Dr. Tuyen Ong M.D., MRCOphth, MBA, Exec. VP & Chief Devel. Officer (Age 43)
When did Nightstar Therapeutics IPO?
(NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
Has Nightstar Therapeutics been receiving favorable news coverage?
Media headlines about NITE stock have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nightstar Therapeutics earned a news impact score of 0.17 on Accern's scale. They also gave news articles about the company an impact score of 47.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Nightstar Therapeutics' major shareholders?
Which institutional investors are selling Nightstar Therapeutics stock?
Which institutional investors are buying Nightstar Therapeutics stock?
How do I buy shares of Nightstar Therapeutics?
Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nightstar Therapeutics' stock price today?
One share of NITE stock can currently be purchased for approximately $15.14.
How big of a company is Nightstar Therapeutics?
Nightstar Therapeutics has a market capitalization of $449.32 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 23 workers across the globe.
How can I contact Nightstar Therapeutics?
Nightstar Therapeutics' mailing address is 81 HARTWELL AVE. SUITE 100, LEXINGTON MA, 02421. The company can be reached via phone at 646-522-8445 or via email at [email protected]
MarketBeat Community Rating for Nightstar Therapeutics (NITE)
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
